NDAORALTABLET
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
LOPRESSOR (metoprolol tartrate) by Rubicon Biotechnology is 12. First approved in 2025.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOPRESSOR (metoprolol tartrate) is a beta-1 selective adrenergic receptor blocking agent used primarily for hypertension and angina management. It works by slowing heart rate and decreasing AV nodal conduction, reducing cardiac workload and blood pressure. The drug's selectivity for beta-1 receptors (particularly at lower plasma concentrations) minimizes respiratory side effects compared to non-selective beta-blockers.
LAUNCH
Early-stage launch product from Rubicon Biotechnology in a moderate-competition market (competitive pressure score: 30), likely requiring full commercialization build-out.
Mechanism of Action
12.1 Mechanism of Action Metoprolol is a beta 1 -selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta 2 -adrenoreceptors, chiefly located in the bronchial and vascular…
Worked on LOPRESSOR at Rubicon Biotechnology? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.